Journal
PET CLINICS
Volume 15, Issue 1, Pages 35-43Publisher
ELSEVIER INC
DOI: 10.1016/j.cpet.2019.08.008
Keywords
PD-1; PD-L1; Cancer; Molecular imaging; immunoPET; Immunotherapy; Checkpoint inhibitors
Funding
- Netherlands Organisation for Scientific Research (NWO) [91617039]
- Dutch Cancer Society (KWF) [10099]
- Radboud Institute Health Science (RIHS) [R0003629]
Ask authors/readers for more resources
Clinical indications for immune checkpoint inhibitor (ICI) therapy are rapidly expanding for various stages of several solid tumors. The success of ICIs results from a complex interplay between cancer cells and their immune microenvironment. PD-1/ PD-L1 PET imaging enables to study of these interactions in the tumor microenvironment in a clinical setting. These noninvasive, sensitive and quantitative tools may play an important role in optimizing ICI efficacy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
